Additionally, both decoy oligonucleotides and the PRKCD inhibitor sotrastaurin demonstrate efficacy in vivo and in vitro, exhibiting synergistic effects when combined with sorafenib, the current standard-of-care drug for HCC. Here, PRKCD is linked to hepatocellular carcinoma.